LIXT Stock Overview
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.22 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$1.58 |
| Beta | -0.29 |
| 1 Month Change | 42.79% |
| 3 Month Change | 55.56% |
| 1 Year Change | -43.03% |
| 3 Year Change | -88.97% |
| 5 Year Change | -94.69% |
| Change since IPO | -92.84% |
Recent News & Updates
Recent updates
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 08
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
May 05Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Jan 20We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
Jul 20Lixte Biotechnology starts enrollment in early-stage lung cancer study
Jun 02Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 25Shareholder Returns
| LIXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | 1.5% | 1.2% |
| 1Y | -43.0% | 1.1% | 24.7% |
Return vs Industry: LIXT underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: LIXT underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| LIXT volatility | |
|---|---|
| LIXT Average Weekly Movement | 20.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIXT's share price has been volatile over the past 3 months.
Volatility Over Time: LIXT's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Bas van der Baan | lixte.com |
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| LIXT fundamental statistics | |
|---|---|
| Market cap | US$7.24m |
| Earnings (TTM) | -US$5.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs LIXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIXT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.09m |
| Earnings | -US$5.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LIXT perform over the long term?
See historical performance and comparison